List view / Grid view
Today’s drug screening methods use one or two types of data. However, disease biology is not replicable by simple screening models because diseases are complex and heterogenous. However, advanced screening methods that process dozens of data sources at one time have uncovered novel hits that have been overlooked across the…
Despite decades without vaccine development in the respiratory syncytia virus (RSV) space, researchers are now homing in on a potential strategy to protect individuals from this disease. Here, Drug Target Review’s Ria Kakkad spoke with Dr Christy Comeaux, Medical Lead (RSV), Janssen, about the challenges associated with RSV vaccine development and her most promising…
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
Swedish researchers have designed synthetic DNA that controls a cells’ protein production using AI.
US scientists have developed a potential medication for the genetic cause of ALS and dementia, that eliminates the mutated segments of RNA.
US researchers showed that the protein: GRP78, implicated in COVID-19 and cancers, is effected by the new drug HA15.
US researchers discovered in a study in mice that augmented drug eliminates cancer cells without causing toxicity.
This article highlights five of the latest findings revealed using CRISPR that could be used in the development or design of new therapies.
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.
Japanese scientists underwent a study exploring trigeminal nerves and how the intranasal administration of the novel glucagon-like peptide-2 can produce antidepressant effects in mice.
A new AI model can accelerate drug discovery by accurately predicting human response to novel drug compounds.
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
The Scripps Research team showed that a variation of an already FDA-approved therapeutic for neurological disease can block COVID-19 infection in animals.
Jiankun Lyu hopes to use algorithms to find improved drugs by screening chemicals that may look different to a protein’s known ligands but work in a similar way.
Using an AI algorithm that models drug and target protein interactions, researchers achieved up to 97 percent accuracy in identifying promising drug candidates.
